GLPwatch
Papers (10382)
Page 118 of 174, ranked by citation count.
- Multiple drug combination of anti-diabetic agents as a predictor for poor clinical response to liraglutide.
- Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.
- Semaglutide Improved Cardiovascular Health in People Without Diabetes.
- Improving management of diabetic kidney disease: will GLP-1 receptor agonists have a role?
- Glucagon-like pepetide-1 receptor agonist suggests novel therapeutic options for hypothalamic obesity.
- Nutrient-Stimulating Hormone-Based Therapies for Obesity.
- GLP-1 receptor agonists and alcohol use disorder: a systematic review.
- Effects of exenatide and liraglutide on postchallenge glucose disposal in individuals with normal glucose tolerance.
- Once-weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis.
- Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.
- Cost-effectiveness analysis of four glucagon-like peptide-1 or glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists for the treatment of adult patients with overweight and obesity in China.
- Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use.
- Comparison of the injection-site experience of semaglutide in a single-dose and a multidose pen-injector.
- Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
- Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
- An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review.
- Therapy for NASH.
- Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.
- Silk fibroin hollow microneedle system for sustained transdermal administration of liraglutide: development and characterization.
- Weighing your options-intragastric balloon versus semaglutide.
- Letter to the Editor: Comment on Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons.
- Weight loss interventions and obesity-associated cancers in people with type 2 diabetes and overweight/obesity: A real-world observational study.
- Semaglutide Improves Heart Failure and Cardiovascular Disease.
- Effect of glucagon-like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: A systematic review and network meta-analysis.
- Acute Exenatide Therapy Attenuates Postprandial Vasodilation in Humans with Prediabetes: A Randomized Controlled Trial.
- Tirzepatide for the treatment of heart failure in Type 2 diabetes mellitus: (SUR)PASS, or not?
- The preclinical discovery and clinical evaluation of tirzepatide for the treatment of type 2 diabetes.
- Lithium Toxicity and Altered Clearance Following Initiation of Semaglutide in Patients With Bipolar Disorder: A Case Series and Literature Review.
- Semaglutide is safe and efficacious for NASH resolution.
- Cyclic Hydroxylamines for Native Residue-Forming Peptide Ligations: Synthesis of Ubiquitin and Tirzepatide.
- Semaglutide (Ozempic) for Type 2 Diabetes Mellitus.
- Liraglutide attenuates doxorubicin-induced cardiomyocyte ferroptosis via DHHC7-mediated STAT3 palmitoylation.
- Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
- In patients with HFpEF and obesity, semaglutide increased weight loss and reduced symptoms and physical limitations at 52 wk.
- Newer Glucagon-Like Peptide-1 Receptor Agonists Are Associated With Improved Glycemic Control in US Adults With Type 2 Diabetes: A Population-Level Time Series Analysis.
- Hypersensitivity Reactions to the GLP-1 Receptor Agonists Liraglutide and Semaglutide: A Case Series.
- Liraglutide for adults living with obesity.
- Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide.
- Treatment of Type 2 Diabetes in Patients with Obesity: A Review.
- Gastrointestinal safety evaluation of semaglutide for the treatment of type 2 diabetes mellitus: A meta-analysis.
- Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity.
- Subcutaneous Semaglutide Use for Weight Management: Practice and Attitudes of Physicians in Israel.
- Semaglutide ameliorates metabolic disorders in offspring via regulation of oocyte ROS of pre-pregnancy obesity mice.
- Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders.
- Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy - a retrospective cohort study.
- Efficacy and safety of combination of semaglutide and basal insulin in patients with of type 2 diabetes mellitus: A systematic review and meta-analysis.
- Semaglutide Improves Lipid Subfraction Profiles in Type 2 Diabetes: Insights from a One-Year Follow-Up Study.
- Blinded by the drug? A vigilyze signal linking semaglutide to NAION.
- Once-Weekly Semaglutide in Adolescents with Obesity.
- Effect of Oral Semaglutide on Volumetric BMD and Bone Microarchitecture in Overweight/Obese Individuals with Type 2 Diabetes.
- Youth Perspectives on the Use of Medications for Weight Loss.
- Exenatide enhances INS-1 rat pancreatic β‑cell mass by increasing the protein levels of adiponectin and reducing the levels of C-reactive protein.
- Insulin Glargine is More Suitable Than Exenatide in Preventing Muscle Loss in Non-Obese Type 2 Diabetic Patients with NAFLD.
- Semaglutide and obesity: beyond the nutritional and lifestyle intervention?
- Liraglutide for patients with non-alcoholic steatohepatitis.
- Effects of exenatide in poorly controlled type 2 diabetes.
- Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations.
- Proinflammatory cytokine-induced alpha cell impairment in human islet microtissues is partially restored by dual incretin receptor agonism.
- Effects of oral semaglutide on cardiovascular outcomes: A systematic review and meta-analysis.
- Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial.